Showing results (91-100 of 335) with videos related to

Sort By:
Pageof 34
The Lancet. Oncology|October 17, 2024
Interchangeability of immune checkpoint inhibitors: an urgent need for actionMichiel Zietse, Roelof W F van Leeuwen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, et al.
Clinical Pharmacokinetics|August 16, 2023
Therapeutic Drug Monitoring of Kinase Inhibitors in OncologyMaud B A van der Kleij, Niels A D Guchelaar, Ron H J Mathijssen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 30, 2022
Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the NetherlandsAnne Kleijburg, C Louwrens Braal, Justin D Westenberg, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 14, 2026
Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practiceSheraz A Ditta, Franny Jongbloed, Olivier C Manintveld, et al.
Cancer Research|April 24, 2014
Influence of drug formulation on OATP1B-mediated transport of paclitaxelAnnemieke J M Nieuweboer, Shuiying Hu, Chunshan Gui, et al.
Oncotarget|December 1, 2016
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patientsXiaoyan Liu, Jesse J Swen, Epie Boven, et al.
European Journal of Clinical Pharmacology|January 15, 2016
Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patientsAstrid W Oosten, João A Abrantes, Siv Jönsson, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 15, 2011
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific bindingPeter de Bruijn, Anne-Joy M de Graan, Annemieke Nieuweboer, et al.
Journal for Immunotherapy of Cancer|February 7, 2023
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short reportKarlijn de Joode, Sharon Veenbergen, Claudia Kransse, et al.
The Pharmacogenomics Journal|February 5, 2019
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumorsMichiel C Verboom, Jacqueline S L Kloth, Jesse J Swen, et al.
Pageof 34